Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study
eLife · 2024
DOI: 10.7554/elife.92655 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift eLife, 2024. Verfasst von Marco Bergamini und 18 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Br…. Hauptthemen laut MEDLINE: Androgen Antagonists, Body Composition, Bone Density, Follicle Stimulating Hormone. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ferring.
Abstract (Originalsprache)
Background
Among its extragonadal effects, follicle-stimulating hormone (FSH) has an impact on body composition and bone metabolism. Since androgen deprivation therapy (ADT) has a profound impact on circulating FSH concentrations, this hormone could potentially be implicated in the changes of fat body mass (FBM), lean body mass (LBM), and bone fragility induced by ADT. The objective of this study is to correlate FSH serum levels with body composition parameters, bone mineral density (BMD), and bone turnover markers at baseline conditions and after 12 months of ADT.
Methods
Twenty-nine consecutive non-metastatic prostate cancer (PC) patients were enrolled from 2017 to 2019 in a phase IV study. All patients underwent administration of the luteinizing hormone-releasing hormone antagonist degarelix. FBM, LBM, and BMD were evaluated by dual-energy x-ray absorptiometry at baseline and after 12 months of ADT. FSH, alkaline phosphatase, and C-terminal telopeptide of type I collagen were assessed at baseline and after 6 and 12 months. For outcome measurements and statistical analysis, t -test or sign test and Pearson or Spearman tests for continuous variables were used when indicated.
Results
At baseline conditions, a weak, non-significant, direct relationship was found between FSH serum levels and FBM at arms ( r = 0.36) and legs ( r = 0.33). Conversely, a stronger correlation was observed between FSH and total FBM ( r = 0.52, p = 0.006), fat mass at arms ( r = 0.54, p = 0.004), and fat mass at trunk ( r = 0.45, p = 0.018) assessed after 12 months. On the other hand, an inverse relationship between serum FSH and appendicular lean mass index/FBM ratio was observed ( r = −0.64, p = 0.001). This is an ancillary study of a prospective trial and this is the main limitation.
Conclusions
FSH serum levels after ADT could have an impact on body composition, in particular on FBM. Therefore, FSH could be a promising marker to monitor the risk of sarcopenic obesity and to guide the clinicians in the tailored evaluation of body composition in PC patients undergoing ADT. Funding: This research was partially funded by Ferring Pharmaceuticals. The funder had no role in design and conduct of the study, collection, management, analysis, and interpretation of the data and in preparation, review, or approval of the manuscript. Clinical trial number: clinicalTrials.gov NCT03202381 , EudraCT Number 2016-004210-10.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
- Division of Urology, Department of Translational Medicine, University of Eastern Piedmont, Maggiore Della Carità Hospital, Novara, Italy.
- Urology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
- Radiation Oncology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
- Tecnologie Avanzate S.r.l, Turin, Italy.
- Radiology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
ORCID-Profile: Marco Bergamini, Alberto Dalla Volta, Davide Farina, Gherardo Mazziotti
Förderung
- Ferring
Zitieren
APA
Bergamini, M., Dalla Volta, A., Palumbo, C., Zamboni, S., Triggiani, L., Zamparini, M., Laganà, M., Rinaudo, L., Di Meo, N., Caramella, I., Bresciani, R., Valcamonico, F., Borghetti, P., Guerini, A., Farina, D., Antonelli, A., Simeone, C., Mazziotti, G., & Berruti, A. (2024). Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study. eLife. https://doi.org/10.7554/elife.92655
Vancouver
Bergamini M, Dalla Volta A, Palumbo C, Zamboni S, Triggiani L, Zamparini M, et al. Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study. eLife. 2024. doi:10.7554/elife.92655
BibTeX
@article{Bergamini2024,
author = {Bergamini, Marco and Dalla Volta, Alberto and Palumbo, Carlotta and Zamboni, Stefania and Triggiani, Luca and Zamparini, Manuel and Laganà, Marta and Rinaudo, Luca and Di Meo, Nunzia and Caramella, Irene and Bresciani, Roberto and Valcamonico, Francesca and Borghetti, Paolo and Guerini, Andrea and Farina, Davide and Antonelli, Alessandro and Simeone, Claudio and Mazziotti, Gherardo and Berruti, Alfredo},
title = {Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study},
journal = {eLife},
year = {2024},
doi = {10.7554/elife.92655}
}
EUVIMED